MedPath

PYC Therapeutics' VP-001 Demonstrates Sustained Vision Improvement in RP11 Patients Following Repeat Dosing

• PYC Therapeutics reports that repeat doses of VP-0014 in RP11 patients sustain the vision improvements initially seen with a single dose. • In two of three patients, the treated eye showed improvement from baseline across all three measured endpoints, outperforming the untreated eye. • The third patient experienced similar improvements in two endpoints, with the treated eye matching the untreated eye in the third endpoint. • No treatment-emergent serious adverse events have been reported in any patient receiving VP-001 to date, including those at the highest dose.

PYC Therapeutics has announced positive interim results from its repeat dose clinical trials of VP-001 for Retinitis Pigmentosa type 11 (RP11). The data indicate that the improvements in vision previously observed after a single dose of VP-0014 have been maintained and, in some cases, enhanced with multiple doses.

Favorable Outcomes in Repeat Dose Study

The interim update focuses on a cohort of patients receiving multiple doses of VP-001. According to PYC Therapeutics, two out of three patients in this cohort demonstrated that the eye treated with VP-001 outperformed the untreated eye and showed improvement from baseline across all three endpoints. The third patient also exhibited positive results, with the treated eye outperforming the untreated eye and improving from baseline in two endpoints, matching the untreated eye's performance in the third endpoint.

Safety Profile

Importantly, PYC Therapeutics reported that no treatment-emergent serious adverse events have been observed in any patient treated with VP-001 to date. This includes patients who have received three doses of the highest administered dose of VP-001, suggesting a favorable safety profile for the drug candidate.

Future Updates

PYC Therapeutics plans to provide a more comprehensive update on the outcomes of these multiple-dose studies in the first half of 2025. This future data release will likely include more detailed analyses of the efficacy and safety data, offering further insights into the potential of VP-001 as a treatment for RP11.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Tenpoint Therapeutics' BRIMOCHOL™ PF Shows Positive Phase 3 Results for Presbyopia

Tenpoint Therapeutics' BRIMOCHOL™ PF met primary endpoints in the BRIO-II Phase 3 trial, demonstrating statistically significant near vision improvement over 8 hours.
The study showed BRIMOCHOL™ PF was well-tolerated with no serious adverse events during the 12-month at-home dosing period.

Perspective Therapeutics and PMV Pharma Provide Clinical Trial Updates

Perspective Therapeutics' VMT-α-NET program shows promising early results in neuroendocrine tumors, with no dose-limiting toxicities observed in Phase 1/2a trials.
Perspective Therapeutics plans to initiate therapeutic dosing of PSV359, a FAP-α-targeted radiopharmaceutical, with potential study enrollment around mid-2025.

PDS Biotech Updates Phase 3 VERSATILE-003 Trial Design for HPV16-Positive HNSCC

PDS Biotechnology has updated the Phase 3 VERSATILE-003 trial design for HPV16-positive recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC), increasing the patient target to approximately 350.
The updated design maintains a 2:1 randomization and median overall survival as the primary endpoint, aligning with the FDA agreement on registrational design.

Replimune's RP1 Plus Nivolumab Shows Promise in Anti-PD1 Failed Melanoma

IGNYTE trial data reveals a 33.6% overall response rate (ORR) by mRECIST v1.1 in melanoma patients who progressed on anti-PD-1 therapy.
The combination of RP1 and nivolumab induced durable responses, with a median duration of response of 21.6 months from response initiation.

Replimune's RP1 Plus Nivolumab Shows Promising Anti-Tumor Activity in Anti-PD-1 Failed Melanoma

Replimune's IGNYTE trial data shows RP1 plus nivolumab achieved a 33.6% overall response rate in anti-PD-1 failed melanoma patients.
The combination therapy demonstrated durable responses, with a median duration of response of 21.6 months from response initiation.

Replimune's RP1 Plus Nivolumab Shows Promise in Anti-PD1 Failed Melanoma

Replimune's IGNYTE trial data reveals a 33.6% overall response rate (ORR) by mRECIST v1.1 in melanoma patients who progressed on anti-PD-1 therapy.
Biomarker analysis indicates that RP1 combined with nivolumab boosts CD8+ T cell infiltration and PD-L1 expression, enhancing anti-tumor immune response.

Rezatapopt Monotherapy Advances in TP53-Mutated Solid Tumors; Combination Arm Discontinued

Rezatapopt monotherapy continues in a phase 2 trial for TP53 Y220C-mutated, KRAS wild-type advanced solid tumors, showing promising early response rates.
A phase 1b trial of rezatapopt combined with azacitidine is planned for recurrent or refractory AML/MDS with TP53 Y220C mutation, starting in early 2025.

EyePoint's DURAVYU Shows Promise in Phase 2 DME Trial

EyePoint Pharmaceuticals reported positive interim results from its Phase 2 VERONA trial of DURAVYU for diabetic macular edema (DME).
DURAVYU 2.7mg demonstrated an 8.9 letter improvement in BCVA and a 68 micron reduction in CST at 16 weeks compared to baseline.

PYC Therapeutics' RNA Therapies Show Promise in Early-Stage Trials for Genetic Eye Diseases

PYC Therapeutics reports positive early-stage trial results for VP-001, an investigational drug targeting Retinitis Pigmentosa type 11 (RP11), with some patients showing vision improvements.
VP-001 has received Orphan Drug Designation from the FDA, potentially granting PYC Therapeutics tax credits and market exclusivity for this treatment.

Novel Therapies for Wet AMD Target Reduced Injection Burden and Broader VEGF Inhibition

4D-150 gene therapy shows a nearly 90% reduction in annualized anti-VEGF injections, with stable visual acuity and CST reduction in Phase 2 interim results.
EYP-1901, an intravitreal tyrosine kinase inhibitor, demonstrates an 80% reduction in treatment burden and stable visual acuity over 12 months in the DAVIO 2 trial.

Reference News

[1]
PYC provides an interim update on progress in RP11 repeat dose clinical trials - Biotech
biotechdispatch.com.au · Oct 22, 2024

PYC Therapeutics reports vision improvements in Retinitis Pigmentosa type 11 patients receiving multiple doses of VP-001...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy